Substantial advances in our understanding of lentivirus lifecycles and their various constituent proteins have permitted the bioengineering of lentiviral vectors now considered safe enough for clinical trials for both lethal and non-lethal diseases. They possess distinct properties that make them particularly suitable for gene delivery in ophthalmic diseases, including high expression, consistent targeting of various post-mitotic ocular cells in vivo and a paucity of associated intraocular inflammation, all contributing to their ability to mediate efficient and stable intraocular gene transfer. In this review, the intraocular tropisms and therapeutic applications of both primate and non-primate lentiviral vectors, and how the unique features of the eye influence these, are discussed. The feasibility of therapeutic targeting using these vectors in animal models of both anterior and posterior ophthalmic disorders has been established, and has, in combination with substantial progress in enhancing lentiviral vector bio-safety over the past two decades, paved the way for the first human ophthalmic clinical trials using lentivirus-based gene transfer vectors.
INTRODUCTION
Lentiviruses are integrating, complex, single-stranded, positive-sense, enveloped RNA retroviruses which, unlike simple retroviruses, can be engineered into vectors, which possess the necessary cellular and molecular components required for stable transduction of both dividing and post-mitotic cells in a broad range of target organs. They can be manufactured to high titre and their genome can be deleted for most potentially pro-inflammatory and pathogenic viral components. Unlike first-generation recombinant adenovirus (rAd) vectors, they do not appear to induce immunological complications after intraocular delivery that can compromise transduced cell viability. 1-3 Furthermore, lentivirus-based vectors have a relatively large transgene-carrying capacity compared with recombinant adeno-associated virus (rAAV) vectors (up to 8-10 versus 4.7 kb, respectively), permitting multi-cistronic codelivery of several therapeutic genes or delivery of therapeutic genes too large to be effectively packaged into rAAV vectors.
Lentiviral vectors derived from primate lentiviruses HIV-1, HIV-2 and simian immunodeficiency virus (SIV) have been evaluated intraocularly. However, despite major advances in improving the bio-safety of these vectors, some concerns remain regarding the possibility, although highly remote, of generating replication-competent lentivirus during vector manufacture for clinical application. Psychological barriers in patients regarding use of HIV vectors in a clinical setting, particularly for therapy of non-lethal disorders, may also be difficult to overcome and could significantly affect recruitment into clinical trials. Some of these concerns could be addressed by using non-primate lentiviral vectors. As lentiviruses are highly speciesspecific, inadvertently manufactured wild-type, non-primate, replication-competent lentivirus would not be expected to replicate in human cells. 4 Intraocularly evaluated non-primate vectors have been developed from equine infectious anaemia virus (EIAV), bovine immunodeficiency virus (BIV) and feline immunodeficiency viruses (FIV). Development of these vectors is reviewed elsewhere. 5, 6 OCULAR TRANSDUCTION PROFILES OF LENTIVIRAL VECTORS The transduction properties of HIV-1, (refs 7-24) HIV-2, (ref. 25) SIV, [26] [27] [28] [29] EIAV, 21, [30] [31] [32] [33] [34] [35] FIV, 24, [36] [37] [38] [39] [40] [41] [42] [43] and BIV 44 vectors incorporating a diverse array of envelope pseudotypes and transgene promoters have been evaluated after in vivo and ex vivo delivery in a variety of animal species (Supplementary Tables 1 and 2 ). Most ocular studies have used vesicular stomatitis virus-G (VSV-G)-pseudotyped vectors incorporating ubiquitous promoters and these are described below unless otherwise stated.
The anatomically compartmentalized nature of the eye, as well as various other factors discussed later, appear to critically determine transduction patterns. The route of vector administration (Figure 1 ), as with non-lentiviral vectors, is therefore highly influential in this regard and can be exploited to target specific cell types. Vectors may delivered topically, intra-stromally, sub-conjunctivally, periocularly, into the anterior chamber (intra-cameral administration), intra-vitreally or sub-retinally (Figure 1 ).
Anterior segment delivery
After intra-cameral delivery in rodents, VSV-G-pseudotyped HIV-1 (refs 8,14,15) and EIAV 30 vectors efficiently transduce the corneal endothelium (CE) and the intrinsically phagocytic trabecular meshwork (TM) (Figure 2) . Rabies-G-pseudotyped EIAV vectors, however, fail to transduce these cells and instead appear to transduce neuronal cells within the anterior segment, albeit with low efficiency. 30 In other species, VSV-G-pseudotyped FIV vectors specifically target the TM. 37, 41, 43 Although an early mild inflammatory response is observed histologically with HIV-1 or EIAV vectors, this appears to be transient and not detected at later time points. There is also no evidence of reduced corneal clarity or increased corneal thickness. 18, 30 These, together with no apparent attenuation of expression in the long-term, point toward there being no significant limiting immune responses to, or corneal endothelial toxicity arising from, intra-cameral administration of these vectors.
HIV-1 and EIAV vectors also consistently and efficiently transduce corneal endothelial cells when delivered ex vivo to donor corneas from a variety of species in culture. [19] [20] [21] In a cultured intact human eye model, FIV or HIV-1 vectors efficiently transduce the TM but result in patchy CE transduction after intra-cameral delivery. 24, 43 Femtosecond laser-assisted corneal stromal pocket creation permits direct vector delivery to this layer, significantly facilitating ex vivo HIV-1 mediated gene delivery to pig corneal stromal keratocytes. 23 Intra-vitreal delivery Intra-vitreal delivery of VSV-G-pseudotyped HIV-1, (refs 8,16,18) FIV 40 or SIV 28 vectors, or VSV-G or rabies-G-pseudotyped EIAV vectors, 30 in rodents or rabbits typically fails to produce efficient intraocular expression (Figure 2 ), although focal transduction of retinal pigment epithelium (RPE) or neurosensory retina cells within the vicinity of the injection site may occur. Inefficient transduction of the CE after intra-vitreal BIV vector administration has been described. 35 Although more widespread intraocular transduction after intra-vitreal delivery has been reported in some studies using HIV-1, (ref. 17) HIV-2 (ref. 25) or FIV 38 vectors, these results do not appear to have been replicated.
Sub-retinal delivery
In contrast to intra-vitreal injection, sub-retinal administration of lentiviral vectors consistently results in efficient and stable transduction of RPE cells in rodents and non-human primates (NHPs). For SIV, 26, 28, 29 and most studies involving HIV-1 vectors, 8, 13, 26, 28, 36, 39, 40, 42, 44, 45 expression is restricted to these cells ( Figure 2 ). Additional transduction of neuroretinal neuronal and glial cells, albeit of variable efficiencies and distributions, is reported using HIV-1, (refs 16-18) HIV-2, (ref. 25) EIAV, (refs 30,33,35) BIV 35 and FIV 36, 39, 40, 42 vectors in rodents, rabbits or NHPs, and by some groups delivering HIV-1 vectors in young rodents 7, 10 (Figure 2 ). Lentiviral Typical transduction profiles of VSV-G-pseudotyped lentiviral vectors harbouring ubiquitous promoters after intraocular delivery in C57Bl/6J mice. Propidium iodide-counterstained (red) cryosections of mouse eyes after HIV-1 or EIAV vectors delivering eGFP (green). In all eyes, a transient inflammatory reaction is typically observed at 1 week after atraumatic vector delivery, but is not evident at later time points. Top left: Corneal section demonstrating efficient transduction of the CE monolayer after intra-cameral delivery of HIV-1.CMV.eGFP. Top middle: Efficient transduction of the murine TM by HIV-1.CMV.eGFP (arrowhead). Transduction of the CE is also evident in this section (arrow). Top right: Absence of reporter gene expression after intra-vitreal injection of HIV.sFFV.eGFP. Bottom left: Atraumatic sub-retinal injection of lentiviral vectors typically results in sustained reported gene expression restricted to the RPE monolayer. Bottom middle: In some eyes, using certain vectors transduction of other retinal cell types is evident using ubiquitous promoters driving reporter gene expression. In this section, transduction of some PR cells (arrowhead) in addition to RPE cells is evident after atraumatic sub-retinal administration of EIAV.CMV.eGFP, a pattern not typical of most studies using HIV-1 vectors. eGFP fluorescence is also evident in the PR inner and outer segments. Bottom right: Traumatic delivery, by intentional creation of retinotomies at the time of sub-retinal vector administration, facilitates transduction of retinal neuronal and glial cells, demonstrating the capacity of lentiviral vectors to transduce neurosensory retinal tissue, and supporting the role of physical barriers in influencing lentiviral vector tropism. Delivery of EIAV.CMV.eGFP in this eye using this approach transduced cells morphologically representing Mü ller cells (arrowhead) and ganglion cells (arrow), and possibly other neurosensory retinal cells. Localized destruction of the ONL secondary to the effects of the deliberate retinal trauma is also evident in this eye. epi, corneal epithelium; str, corneal stroma; end, corneal endothelium; cb, ciliary body; scl, sclera; gcl, ganglion cell layer; inl, inner nuclear layer; onl, outer nuclear layer; is, PR inner segment layer; os, outer segment layer; rpe, retinal pigment epithelium layer; ac, anterior chamber; iv, intra-vitreal; sr, sub-retinal; ir, intra-retinal.
vectors with the capacity to transduce photoreceptors (PRs) and/or other retinal cells may possibly, therefore, have wider retinal applications than HIV-1 vectors, although this will be critically dependent on their PR transduction efficiencies, which currently do not rival those obtained using current rAAV serotypes. Nonetheless, the PR transduction efficiency of EIAV vectors has recently been reported to be sufficient to rescue Abca4 (À/À) mice, 34 a model for PR-specific recessive Stargardt macular dystrophy caused by mutations in ABCA4 (PR-specific ATP-binding cassette transporter-4), which being 8.9 kb in size, cannot be efficiently packaged into existing rAAV serotypes (see clinical trials). Factors underlying the variations in observed spatial transduction patterns after intraocular delivery are discussed below.
Delivery to NHPs
Vector evaluation in large animal eyes is desirable owing to their greater anatomical similarities with human eyes. NHPs also possess greater immunological and biological similarity to humans, permitting more accurate pre-clinical evaluation of vector characteristics and tolerance. The NHP is especially attractive for vector assessment, as it ocular anatomy is highly comparable to human eyes, and in particular, as it also possesses a macula. In addition, surgical procedures for vector administration, including quantity of vector required, will be similar to procedures in patients. 46 Studies in NHPs using ubiquitous promoters suggest sustained retinal gene transfer using FIV (PRs and Müller cells), 36 SIV (RPE ± PRs) 27 and EIAV (RPE and PRs) 35 vectors after vitrectomy and sub-retinal administration, although with varying efficiencies of transduction (Supplementary Table 1 ). Intra-cameral delivery using FIV vectors predominantly transduces the TM. 37 The effects of intra-vitreal delivery of lentiviral vectors in NHPs have not been reported.
Expression kinetics
Although the reported spatial transduction patterns of lentiviral vectors show some variation for a given vector between different laboratories, and between different vectors, lentiviral vectors show greater consistency in terms of their expression kinetics, typically producing rapid and sustained transgene expression. For example, efficient expression is evident as early as 3 days and persists until at least 16 months after sub-retinal administration of EIAV vectors. 30 Expression up to at least 4 years without noticeable decline has been reported in NHPs receiving sub-retinal SIV vectors. 27 
FACTORS INFLUENCING INTRAOCULAR TRANSDUCTION AND EXPRESSION CHARACTERISTICS
The observed spatial and temporal transduction and expression characteristics of lentiviral vectors may be influenced by the their natural tropism, vector particle size, target cell and vector receptor profiles, vector genome configuration and titre, promoter selection, site of vector delivery and anatomical barriers to vector dispersion, and the species and maturity of the test organ system. While their natural tropism may be influenced by their particle size, it is critically affected by their complement of surface envelope proteins, which is in turn determined by their pseudotyping. Recognition of specific complementary receptors on target ocular cells would be required for vector internalization, with the possible exceptions of intrinsically phagocytic TM and RPE cells. Particle size, which may also be influenced by the pseudotyping envelope, 47 and micro-anatomical barriers, including the outer limiting membrane and the inter-photoreceptor matrix, are likely to be contributory mechanisms underlying why rAAV 2/2 vectors (approximately 20 nm in size) 48 but not VSV-G-pseudotyped HIV-1 vectors (80-120 nm 49 ) readily transduce PRs after sub-retinal delivery. Similarly, the inner limiting membrane and possibly the posterior hyaloid face of the vitreous cortex may prohibit lentiviral transduction of retinal cells after intra-vitreal delivery, with the anterior hyaloid face and lens zonules potentially being effective barriers to vector diffusion into the anterior segment after this mode of delivery. Thus, ocular compartmentalization at both macroscopic and microscopic levels may effectively limit vector spread between adjacent ocular compartments, contributing to the differences in transduction patterns observed after different routes of vector administration.
The reported tropisms of a given vector system can vary between laboratories, and one factor that may underlie these differences may relate to the precise method of vector delivery, in particular, the degree of iatrogenic injection-associated ocular trauma. Focal transduction of retinal cells after sub-retinal delivery in the vicinity of the injection site appears to be a common finding, and may conceivably occur because of the physical breakdown by trauma of anatomical barriers, allowing direct vector access to these cells, and/or be facilitated by secondary changes in the local cellular environment. This hypothesis was investigated in one study, 30 which aimed to enhance lentiviral vector access to neurosensory retinal cells after sub-retinal and intra-vitreal delivery by deliberate surgical retinal trauma, and potentially focally overcoming purported anatomical barriers, including the vitreous cortex, the inter-PR matrix, 50 and the inner and outer limiting membranes. 28 This intra-retinal delivery of VSV-G-or rabies-Gpseudotyped cytomegalovirus (CMV) promoter-harbouring EIAV vectors transduced PRs, Müller cells and ganglion cells within the vicinity of the injured areas (Figure 2 ), and resulted in reporter gene expression within the optic nerve and chiasm, confirming the ability of EIAV vectors to transduce neuroretinal cells, and supporting the role of physical barriers in influencing vector transduction profiles. 30 Clinical implications of this include the opportunity to target transduction to sites of retinal injury associated with pre-existing retinal tears, as well as the possibility of undesirable transduction of non-target retinal cells at the site of a surgical retinotomy created for vector delivery to the sub-retinal space. It also follows that surgical removal of the posterior vitreous hyaloid and inner limiting membranes, clinical techniques routinely performed for certain vitreoretinal disorders, may facilitate transduction of some neurosensory retinal cells after intra-vitreal vector administration. Likewise, surgical disruption of the anterior hyaloid vitreous face could facilitate access to the anterior segment after intra-vitreal delivery, if required. Similarly, anatomical barriers appear to prevent corneal stromal keratocyte transduction after conventional intracameral delivery, but can be overcome by surgically exposing the stroma, for example with the use of a femtosecond laser, permitting direct vector access and transduction of this tissue. 23 The influences of retinal maturity at the time of vector administration, or of host species upon vector tropisms, are not consistent. The transduction efficiencies of HIV-1 vectors were generally greater in animals injected at p4-5 than those injected as adults. 10 While PR transduction frequency appears substantially 7 or slightly 8 higher in rodents receiving HIV-1 vectors at p2-7 than in adults, this was not reproduced using EIAV vectors. 30 It remains possible, however, that administration of EIAV or other lentiviral vectors at even earlier stages in retinal maturation may uncover some age dependence for vector expression profiles.
Promoter selection is dictated by the levels, specificities and durations of transgene expression desirable for a given therapeutic application. The incorporation of constitutive promoter sequences in the design of lentiviral vectors would be expected to result in continuous and ubiquitous transgene expression in transduced cells, in contrast to cell-specific, pharmacologically regulated or tissue environment-sensitive promoters. However, several studies suggest that some 'ubiquitous' promoter sequences, including CMV, may not be constitutively active in all retinal cells in vivo with all vectors systems; that in some instances, their activities may be vector system-dependent. These studies suggest that sub-retinally injected HIV-1 (ref. 16) 
Sequences also vary in their degree of inherent promoter activity and can be selected to achieve the desired levels of expression for a given disease application; levels, which may be above, below or comparable to physiological levels. Abbreviations: CAG, combination of the cytomegalovirus (CMV) early enhancer element and chicken b-actin promoter; bPDE, b-phosphodiesterase; AC, anterior chamber (intra-cameral); CBA, chicken b-actin promoter; CMV, cytomegalovirus; CMV/CBA hybrid promoter; CNTF, ciliary neurotrophic factor; COX-2, cyclooxygenase-2; FPR, FP receptor; hFGF, human fibroblast growth factor; hPGK, human phosphoglycerate kinase-1; IDO, indoleamine indoleamine-2,3-dioxygenase; IV, intra-vitreal; OIR, oxygen-induced retinopathy; PEDF, pigment epithelium-derived growth factor; PGFS, prostaglandin synthase; PGK, phosphoglycerate kinase-1; RCS, Royal College of Surgeons; Rho, rhodopsin; RPE, retinal pigment epithelium; RPE08, 823 -bp human RPE RPE-specific promoter; sFFV, spleen focus focus-forming virus; sFlt-1, soluble fms-like tyrosine kinase-1; SR, sub-retinal; SV40, simian virus virus-40; VSV-G, vesicular stomatitis virus G G-glycoprotein. a Unpublished.
THERAPEUTIC APPLICATIONS OF LENTIVIRUS-MEDIATED OCULAR GENE TRANSFER
various neurosensory retinal cells, including PRs and Müller glia. Diseases of non-transducible adjacent cells could also be targeted if, for example, a sufficient paracrine therapeutic effect could be achieved by a secreted gene product synthesized by neighbouring transduced cells. The large carrying capacity of lentiviral vectors may permit codelivery of multiple genes, facilitating multifaceted targeting of disease processes with potentially greater therapeutic effects than single gene delivery approaches.
Anterior segment applications
Anterior segment applications would follow from efficient gene delivery to the CE and stroma, and the TM, allowing, therefore, treatment of corneal disorders, delivery of immunomodulatory therapies for anterior uveitis, delivery of antiangiogenic genes for rubeosis irides or TM modulation in glaucoma.
Cornea. The CE is a terminally differentiated monolayer that has a crucial role in maintaining corneal transparency, and is also the principal cell type adversely affected during corneal allograft rejection. Dysfunction or loss results in corneal oedema, reduced vision and eventually corneal scarring. The cornea, unlike posterior segment tissues, readily presents the opportunity for ex vivo gene delivery, a safer and potentially more efficient and targeted delivery method than direct in vivo administration, and which may be particularly useful for corneal endothelial disorders which require corneal allograft transplantation. This approach also permits the removal of all transduced tissue should toxicity arise. The cornea is an attractive target, therefore, for gene delivery in the development of novel therapies for CE failure and graft rejection, as well as for anterior segment inflammatory and neovascular disorders. Immunomodulatory and angiostatic genes could be delivered to address the key factors for rejection, namely inflammation, previous immune rejection and corneal neovascularization. As the success of primary allografting is high, genetic modulation could be reserved for high-risk cases. HIV-1, or EIAV vectors, have been evaluated in vivo and ex vivo to deliver a diverse array of immunomodulatory, angiostatic or other genes in models of corneal allograft transplantation, corneal neovascularization, corneal haze or herpetic stromal keratitis (reviewed in detail in Klausner et al. 65 ; Williams and Coster 66 ). Femtosecond laser technology, which is in widespread clinical use in refractive surgery, could be used ex vivo or in vivo to facilitate gene delivery, permitting molecular treatment of stromal disorders, angiogenic processes and inhibition of corneal scarring.
Glaucoma. The glaucomas are the second most common cause of irreversible blindness in the world. An increased resistance to aqueous humour outflow through the TM and Schlemm's canal is chiefly responsible for the majority of cases, and is associated with irreversible loss of retinal ganglion cells. Current therapies are all directed at lowering intraocular pressure, and typically require lifelong administration. The chronic nature of these disorders, which frequently progresses despite therapy, together with often poor patient compliance with long-term treatment regimes, and an improved understanding of their molecular bases, makes them candidate diseases appropriate for further development of gene therapeutic approaches.
The consistently high transduction of the TM by lentiviruses, and their ocular tolerance after intra-cameral administration, make them particularly suitable for further development. Strategies (reviewed in detail by Liu et al. 67 ) could be developed to increase aqueous outflow through the various implicated pathways, inhibit aqueous production and inhibit scarring after filtration surgery, or be developed to augment neuroprotection mechanisms promoting retinal ganglion cell survival, for example, by the inhibition of retinal ganglion cell apoptosis. However, knowledge of the pathogenic mechanisms in this group of diseases is limited compared with those involved in retinal degeneration, and a greater understanding is required before rational, targeted, clinically effective molecular therapies are developed.
Posterior segment applications
Although retinal applications for lentiviral vectors are more limited than for rAAV vectors, which, unlike lentiviral vectors, transduce PRs with very high efficiency, lentiviral vectors remain, nonetheless, potentially suitable for treatment of some monogenic inherited retinopathies, and for complex multifactorial diseases, including posterior uveitis and exudative age-related macular degeneration (eAMD). The specific tropism of many lentiviral vectors for the RPE is particularly advantageous for treatment of RPE disorders, whereby possible toxicity due to inadvertent transgene expression within neighbouring neuroretinal cell types is minimized, and which could be further diminished by incorporation of RPE-specific promoters. The high levels of expression typically observed with lentiviral vectors may also necessitate lower doses than with vectors such as rAAV 2/2.
Retinal degeneration. Replacement of genes encoding critical enzymes or chaperones involved in phototransduction (for example, bPDE and RPE65), or PR outer segment turnover (MERTK), by HIV-1 vectors using constitutive promoters is reported to successfully restore function in several recessive models of retinitis pigmentosa ( Choroidal neovascularization. Despite impressive results with some novel anti-VEGF (vascular endothelial growth factor) pharmacotherapies for eAMD, in particular with ranibizumab, there is clearly ample room and requirement for continued optimization of biological eAMD treatments, both in terms of further improving efficacy and patient compliance, and for reducing dosing frequency and associated cumulative expenses and complications. Most viral gene transfer approaches to choroidal neovascularization (CNV) have been designed to alter the net balance of angiostatic and angiogenic factors, which critically determines the angiogenic phenotype. 68 Sufficient overexpression of angiostatic genes or downregulation of pro-angiogenic factors could therefore be therapeutic. Numerous genes have been evaluated in different models using rAd and rAAV vectors, and those which have been delivered by lentiviral vectors are shown in Table 1 . Current clinical pharmacological therapies for CNV seldom induce neovascular regression, and experimental therapies involving single angiostatic gene transfer fail to uniformly completely inhibit angiogenesis. While suboptimal responses could be secondary to insufficient blockade of the targeted pathway, it is more likely that residual neovascularization arises from co-existing, independent angiogenic mechanisms uninhibited using monotherapeutic approaches. Combination angiostatic gene delivery, as may be achieved within a single lentiviral vector, 31 could provide a more robust approach for inducing and sustaining neovascular resolution. Furthermore, achieving sufficient angiostasis in eAMD may require significant transgene overexpression. While this could be achieved by using strong cellular promoters, this would be facilitated by the use of lentiviral vectors, which typically mediate high expression levels. The rapid expression obtained with lentiviral vectors would also be advantageous, as clinical experience suggests that pharmacological intervention within a few weeks in patients with newly symptomatic eAMD is desirable to minimize visual loss 69 and cumulative retinal damage secondary to exudation and/or haemorrhage. These properties, combined with consistent and stable transduction of RPE cells, which are in close anatomical proximity to choroidal neovascular endothelial cells, make lentiviral vectors particularly attractive for development into therapies targeting CNV.
The EIAV vector has been the most developed lentiviral vector system for ocular therapy. EIAV vectors delivering sFlt-1, angiostatin or endostatin resulted in 50-60% reduction in the anatomical extent of laser-induced CNV and 20-60% reduction in associated-vascular hyper-permeability compared with control vector groups (Balaggan et al., 60 and unpublished data). More recently, co-delivery of angiostatin and endostatin by EIAV vectors carrying either CMV or VMD2 promoters significantly inhibited CNV, with a trend suggesting greater efficacy than endostatin delivery alone. 31 This combination vector has been further developed for clinical evaluation in the first lentiviral vector ocular gene therapy trial (see below).
Uveitis. Uveitis refers to a spectrum of relapsing/remitting or chronic disorders affecting the anterior and/or posterior segments, which if severe, can result in significant visual loss. The mainstay of treatment is immunosuppression, usually with topical, intra-vitreal or periocular steroids, or with systemic steroids or steroid sparing agents, which occasionally require administration at high doses. Despite treatment, some cases may progress or require long-term treatment, and often result in well-characterized ocular or systemic side effects. Many inflammatory cytokines and chemokines have been implicated in these disorders (reviewed by Curnow and Murray 70 ). Compared with CNV, there is a paucity of studies evaluating the role of lentivirus-mediated gene transfer as a potential alternative long-term strategy. HIV-1-mediated overexpression of interleukin-10 or interleukin-1 receptor antagonist has, however, been demonstrated to reduce inflammatory cell counts and preserve the blood-aqueous and blood-retinal barriers in the endotoxin-induced model of uveitis. 15 Neuroprotection. The goal of neuroprotective strategies is not gene correction but to limit secondary structural and functional consequences by generic mechanisms. Neuroprotection naturally lends itself to the treatment of most inherited retinopathies, but could also significantly contribute to the management of multifactorial diseases, including glaucomatous optic neuropathy and AMD, in which enhancing neuronal survival would be anticipated to correlate with preservation of visual function. The carrying capacity of lentiviral vectors could potentially be exploited to permit co-delivery of neuroprotective genes in addition to those required for gene correction/angiostasis, thus providing a multifaceted approach to enhancing therapeutic outcomes. Lentivirus-mediated neuroprotection for retinitis pigmentosa has been explored using SIV vectors in which PEDF and/or hFGF overexpression in rodent models of RPE or PR dystrophies inhibits PR degeneration. 63, 64 Vectors could also be developed to deliver GDNF, the delivery of which by rAAV vectors has been demonstrated to be an effective adjunct to gene replacement in several models. 71 For treatment of CNV, delivery of PEDF is a particularly attractive strategy in view of its combined neurotrophic and potent angiostatic properties. 29 RECENT ADVANCES AND FUTURE DIRECTIONS Tremendous advances (reviewed in Srinivasakumar 5 ; Wanisch and Yanez-Munoz 72 ) over the past two decades in lentiviral vector bio-safety, both in terms of reducing the possibility of recombination-induced wild-type or novel replication-competent lentivirus formation, 73 and reducing the risks of insertional mutagenesis (IM), have permitted the translation of basic vectorology towards the first ophthalmic clinical trials using lentiviral vectors. Key recent advances are discussed below.
Reducing the risk of IM Malignant cellular transformation is the principal concern associated with integrating vector-mediated gene transfer, and may arise from retrovirus-induced insertional events stimulating oncogene transactivation as has occurred clinically, 74 or, as is more likely using lentiviral vectors, from tumour-suppressor gene inactivation. Reassuringly, primary malignancies of ocular cells efficiently transduced by lentiviral vectors, including the CE, TM and RPE, have not been described, and spontaneous neuroretinal malignancy (retinoblastoma) only develops in early childhood.
Lentiviral vectors typically exert less preference for promoter site integration than oncoretroviral vectors, and may therefore pose a lower risk for IM. 75 HIV-1 or EIAV vectors in vitro, for example, consistently favour integration into active coding regions in dividing human cell lines, unlike retroviral MoLV vectors, which favour integration near transcriptional start sites. [76] [77] [78] HIV-1 integration in (post-mitotic) murine or rat RPE in vivo does not appear to show site preference for these regions, and instead shows near-random and uniform frequency of integration into genes and gene spare long interspersed nuclear elements, 79 suggesting that the risk of integrating HIV-1-related IM in post-mitotic tissues is probably low, and lower than in mitotically active cells. The in vivo intraocular vector integration profiles of lentiviruses other than HIV-1 have not been reported, but are also likely to be influenced by the degree of target cell mitosis. Furthermore, intraocular administration of high-titre integrating HIV-1 vectors in p53 À/À tumour-suppressor gene-knockout mice, which have a heightened susceptibility for intraocular malignant transformation, does not appear to induce such complications. 80 Recent refinements to lentiviral vector design may further minimize this potential risk, which is inherent to integrating vectors, and include curtailing integration-induced transactivation of neighbouring cellular genes, for example, by long terminal repeat deletion or embedded transcription and insulation, or by spatially restricting transgene expression using cell-specific promoters. 81 For long-term applications not requiring vector integration, principally treatment of diseases of post-mitotic cells, including many ocular cells, an attractive additional strategy to reduce the risk of IM involves selective disruption of vector integration. This may be achieved by engineering class-I mutations, for example, D64V, into the catalytic core domain of integrase, substantially disrupting its integration activity while preserving its other critical roles. 82 Novel D64V integrase mutation-harbouring HIV-1 vectors efficiently and stably mediated longterm intraocular transgene expression in mice and rescued two rodent models of retinitis pigmentosa, with transduction profiles and efficacies comparable to their titre-matched integrating counterparts, but with substantially reduced genomic integration in vivo. 18 This proof-ofprinciple demonstration of stable in vivo expression from these vector forms was subsequently confirmed in other rodent post-mitotic tissues in vivo, including CNS, 18,83,84 muscle 85 and liver, 86 as well as dog retina. 84 Integration-deficient vectors may also be produced by engineering non-pleiotropic mutations in the att sites, the chromosomebinding site and the viral DNA-binding site of integrase. Although these vectors sustain efficient and stable transduction of muscle in vivo, 85 they remain to be evaluated intraocularly. In addition to reducing the risk of IM, inadvertent germline transmission owing to systemic vector escape after in vivo administration would be minimized by using integrasedeficient vectors, as their episomes lack replication signals resulting in rapid vector genomic dilution secondary to mitosis.
Non-integrating, non-primate vectors with at least comparable transduction and expression profiles to integrating vectors would theoretically compliment the potential advantages of non-primate vectors in terms of the effects of possible replication competence, with additional bio-safety with respect to IM provided by deficient integration. A non-integrating SIV vector has been described recently. 87 Clinical trials for eAMD and Stargardt macular dystrophy using non-primate lentiviral vectors Considerable progresses in lentiviral vector development and promising pre-clinical efficacy and safety profiles have permitted the initiation of the first ocular clinical trials using lentiviral vectors. Retinostat is a bicistronic EIAV vector delivering both endostatin and angiostatin under the control of the RPE-specific VMD2 promoter, and has shown favourable pre-clinical efficacy and safety profiles. 88, 89 A phase-I dose-escalation study involving a single sub-retinal injection of viral vectors administered trans-retinally during pars plana vitrectomy in patients with clinically active advanced eAMD is currently recruiting, with an estimated primary completion date of June 2012 (Clinical trials.gov identifier NCT01301443). Stargardt disease is the most common juvenile retinal degeneration, with a US and EU prevalence of approximately 80-100 000 patients, and has been discussed earlier. Phase-I/IIb dose-escalation evaluation of Stargen, which consists of the EIAV vector delivering ABCA4 in Stargardt patients with at least one pathogenic mutation in the ABCA4 gene on each chromosome, is also currently underway, with an estimated completion date of October 2013 (Clinical trials.gov identifier NCT01367444).
CONCLUSION
In the 14 years since the first intraocular evaluation of a lentiviral vector, 7 the range of available vectors and vector pseudotypes, and therefore the range of transducible cells and potentially amenable ophthalmic disorders, have expanded. Both primate and non-primate lentiviral vectors consistently mediate efficient and sustained intraocular transgene expression across a broad range of species. Substantial advancements in vector engineering to enhance transgene expression, expression specificity and vector titres, and to minimize residual viral sequences and the risks of vector integration and of current manufacturing methods, have been achieved during this relatively short period. There is also now significantly wider preclinical understanding in terms of therapeutic applications and vector toxicology. Although there is currently greater clinical experience with rAAV 2/2 than lentiviral vectors, valuable clinical safety data for lentiviral vectors will become available over the next few years. As with all such trials, rigorous safety and efficacy data monitoring and analysis will be required, and will hopefully endorse the development and clinical evaluation of lentiviral vectors for eAMD and other inherited and acquired ophthalmic disorders. Further support may also be provided if recently described bio-safety enhancements are incorporated into future clinical-grade vector designs. Relevant disorders would include those for which the distinct features of these promising vectors, including their rapid and high levels of expression, their large carrying capacities or the naturally restricted spatial transduction profiles of some vectors, would be envisaged to be advantageous or essential.
